Biomonitor is proud to present the first IVD cell-based assay kits for NAb detection

 iLite^TM anti-human IFN-beta-1a - used  for the detection of Neutralizing antibodies against IFN-beta-1a 

                                                                   and

 iLite^TM anti-human IFN-beta-1b - used  for the detection of Neutralizing antibodies against IFN-beta-1b 

Prolonged therapies with many biopharmaceuticals, including IFN-alpha and IFN-beta, often lead to development of neutralizing antibodies (NAb).

The development of these NAbs is a problem which if not recognized may jeopardize therapeutic efficacy of the IFN treatment and cause side effects from local and/or circulating immune complexes.

Treatment with the above mentioned IFN biopharmaceuticals is costly. Monitoring patients for antibody development is therefore both rational and cost-effective.

• The application of these rapid and robust cell-based assays include
• Clinical Research for Immunogenicity testing Patient monitoring

Click here for details

We are pleased to announce that as of March 2010, Biomonitor A/S has completed Round C private placement with the Danish venture capital company Sunstone Capital A/S.

For further information please contact:
Arsalan Kharazmi, CEO, Biomonitor A/S. E-mail: ak @ biomon.dk, Phone: +45 39179797
Søren Lemonius, Partner, Sunstone Capital A/S, E-mail: Lemonius @ sunstonecapital.com, Phone: +45 40814889